A Study of AK131 in Patients With Advanced Solid Tumors
NCT06166888 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 130
Last updated 2024-01-17
Summary
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
Conditions
Interventions
- DRUG
-
AK131
AK131 is an anti-PD-1 and CD73 bispecific antibody
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-10
- Primary Completion
- 2026-08-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
NCT04172506 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of AK112 in Advanced Malignant Tumors
NCT05214482 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
NCT04547101 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
NCT05235542 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
NCT02836834 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
NCT05223231 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
NCT04068519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
NCT05420220 ·Status: RECRUITING ·Phase: PHASE2
-
Risk Factors and Long-term Impact of ICIs
NCT05754983 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
NCT03852823 ·Status: UNKNOWN ·Phase: PHASE1
-
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
NCT05116007 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
NCT05229497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of AK-1286 in Patients With Advanced Solid Tumors
NCT06779045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
NCT04220307 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
NCT06519669 ·Status: TERMINATED ·Phase: NA
-
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
NCT06031597 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
NCT03086174 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
NCT05142423 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
NCT03908814 ·Status: UNKNOWN ·Phase: PHASE1
-
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
NCT06404281 ·Status: RECRUITING ·Phase: PHASE1
-
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
NCT06088004 ·Status: RECRUITING ·Phase: PHASE1/PHASE2